Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.29252/rbmb.9.1.97 http://scihub22266oqcxt.onion/10.29252/rbmb.9.1.97 32821757!7424417!32821757     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32821757&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Rep+Biochem+Mol+Biol 2020 ; 9 (1): 97-105 Nephropedia Template TP {{tp|p=32821757|t=2020. ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review |pdf=|usr=}}{{32821757}} gab.com Text ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review JO: Rep Biochem Mol Biol http://www.kidney.de/pget.php?&tw=1&pmid=32821757 #FOAvip BACKGROUND: Since its first appearance in December of 2019, regular updates around the world demonstrates that the number of new Corona Virus 2019 (COVID-19) cases are increasing rapidly, indicating that not only does COVID-19 exhibit a rapid spread pattern, but human intervention is necessary for its resolution. Up until today (27-5-2020) and according to the World Health Organization (WHO), the number of confirmed COVID-19 cases has surpassed 4.5 million with more than 307, 500 deaths. Almost all countries have been affected by COVID-19, and resultingly, various drug trials have been conducted, however, a targeted treatment remains to be made accessible to the public. Recently, Angiotensin-Converting Enzyme-2 (ACE2) has gained some attention for its discovery as a potential attachment target of COVID-19. METHODS: We reviewed the most recent evidence regarding ACE2 distribution and action, the binding mechanism of COVID-19 and its correlation to cellular injury, ACE2 polymorphisms and its association to fatal COVID-19 and susceptibility and, finally, current ACE2-based pharmacotherapies against COVID-19. RESULTS: Blocking the ACE2 receptor-binding domain (RBD) using a specific ligand can prevent COVID-19 from binding, and consequently cellular entry and injury. Comparatively, soluble ACE2, which has a higher affinity to COVID-19, can neutralize COVID-19 without affecting the homeostatic function of naturally occurring ACE2. Lastly, ACE2 mutations and their possible effect on the binding activity of COVID-19 may enable researchers to identify high-risk groups before they become exposed to COVID-19. CONCLUSION: ACE2 represents a promising target to attenuate or prevent COVID-19 associated cellular injury. Twit Text FOAVip ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review ????Rep Biochem Mol Biol http://www.kidney.de/pget.php?&tw=1&pmid=32821757 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32821757 #FOAvip English Wikipedia <ref>{{Cite pmid|32821757}}</ref> ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review #MMPMID32821757 Mostafa-Hedeab G Rep Biochem Mol Biol 2020[Apr]; 9 (1): 97-105 PMID32821757show ga BACKGROUND: Since its first appearance in December of 2019, regular updates around the world demonstrates that the number of new Corona Virus 2019 (COVID-19) cases are increasing rapidly, indicating that not only does COVID-19 exhibit a rapid spread pattern, but human intervention is necessary for its resolution. Up until today (27-5-2020) and according to the World Health Organization (WHO), the number of confirmed COVID-19 cases has surpassed 4.5 million with more than 307, 500 deaths. Almost all countries have been affected by COVID-19, and resultingly, various drug trials have been conducted, however, a targeted treatment remains to be made accessible to the public. Recently, Angiotensin-Converting Enzyme-2 (ACE2) has gained some attention for its discovery as a potential attachment target of COVID-19. METHODS: We reviewed the most recent evidence regarding ACE2 distribution and action, the binding mechanism of COVID-19 and its correlation to cellular injury, ACE2 polymorphisms and its association to fatal COVID-19 and susceptibility and, finally, current ACE2-based pharmacotherapies against COVID-19. RESULTS: Blocking the ACE2 receptor-binding domain (RBD) using a specific ligand can prevent COVID-19 from binding, and consequently cellular entry and injury. Comparatively, soluble ACE2, which has a higher affinity to COVID-19, can neutralize COVID-19 without affecting the homeostatic function of naturally occurring ACE2. Lastly, ACE2 mutations and their possible effect on the binding activity of COVID-19 may enable researchers to identify high-risk groups before they become exposed to COVID-19. CONCLUSION: ACE2 represents a promising target to attenuate or prevent COVID-19 associated cellular injury. ?ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Re(epmc).pdf DeepDyve Pubget Overpricing